EyePoint Pharmaceuticals, Inc. — Director's Dealing 2025

Jan 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2025-01-03

Reporting Person: Elston George (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-05	Common Stock	M	15000.00	$0.00	Acquired	63356.00	Direct
2025-01-05	Common Stock	F	5267.00	$8.26	Disposed	58089.00	Direct
2025-01-06	Common Stock	M	15285.00	$0.00	Acquired	73374.00	Direct
2025-01-06	Common Stock	F	4808.00	$8.68	Disposed	68566.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-03	Restricted Stock Units	$0.00	A	59000.00	Acquired		Common Stock (59000.00)	Direct
2025-01-03	Stock Option (Right to Buy)	$8.26	A	117000.00	Acquired	2035-01-03	Common Stock (117000.00)	Direct
2025-01-05	Restricted Stock Units	$0.00	M	15000.00	Disposed		Common Stock (15000.00)	Direct
2025-01-06	Restricted Stock Units	$0.00	M	15285.00	Disposed		Common Stock (15285.00)	Direct

Footnotes

F1: Includes 876 shares acquired on July 31, 2024 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.

F2: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

F3: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026.

F4: The option to purchase will vest and become exercisable as follows: 25% at January 3, 2026 and the remainder ratably, on a monthly basis, over the remaining three years.

F5: The restricted stock units vests in three ratable annual installments beginning January 5, 2025.

F6: The restricted stock units vests in three ratable annual installments beginning January 6, 2024.